Lu X, Zhou ZY, Xin Y, Wang MJ, et al. Matching-Adjusted Indirect Comparisons of Filgotinib vs Vedolizumab, Tofacitinib, and Ustekinumab for Moderately to Severely Active Ulcerative Colitis. Inflamm Bowel Dis 2023 Mar 22:izad037. doi: 10.1093.
PMID: 36946138